Summary
This prediction ended on 19.03.18 with a price of €14.55. During the runtime of the prediction for GSK plc the price only changed by 0.20%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | -4.052% | -4.052% | 27.853% | 28.325% |
| iShares Core DAX® | 0.191% | 4.771% | 20.559% | 64.548% |
| iShares Nasdaq 100 | -0.614% | 3.137% | 5.816% | 110.363% |
| iShares Nikkei 225® | 0.599% | 8.016% | 21.913% | 55.210% |
| iShares S&P 500 | -0.036% | 3.593% | 3.588% | 70.174% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.